Latest Regulatory Submissions News

Page 1 of 29
The US FDA has refused to lift the clinical hold on Argenica Therapeutics’ xaranetide stroke program, demanding a GLP rat neurotoxicity study and imposing a lower exposure limit than the company proposed for Phase 2b. Argenica plans to challenge parts of the assessment while pursuing regulatory submissions elsewhere.
Ada Torres
Ada Torres
19 Nov 2026
Neurizon’s first participant in the 250-person Regimen I ALS trial has completed the 36-week randomised phase and entered an optional active treatment extension. The milestone keeps the program on track for topline results in late Q2 2027, while recent FDA feedback points to a potential single-trial approval pathway if the data meet regulatory standards.
Ada Torres
Ada Torres
13 Nov 2026
Audalia Resources has lodged the key development and closure proposal for its Medcalf titanium-vanadium-iron project in Western Australia. The milestone advances the permitting process, but construction, financing and production remain dependent on further approvals and a final investment decision.
Maxwell Dee
Maxwell Dee
11 Nov 2026
Moderna returned to quarterly GAAP profit, raised its 2026 revenue growth outlook and reported positive Phase 3 melanoma data. The stronger quarter was supported by international COVID vaccine sales, while cash generation and pipeline execution remain important tests.
Ada Torres
Ada Torres
6 Nov 2026
BTC Health has expanded its exclusive ExoVasc PEARS distribution rights from Australia into India under a new five-year agreement. The opportunity is potentially significant, but Indian sales remain dependent on CDSCO import approval.
Ada Torres
Ada Torres
6 Nov 2026
Neuren has lifted its 2026 trofinetide income guidance to US$91 million-US$93 million after Acadia reported a 39% rise in Q3 DAYBUE sales and a US$35 million German launch milestone. Japan trial results also support a planned 2027 regulatory filing, although a launch remains subject to approval and a distribution partner.
Victor Sage
Victor Sage
5 Nov 2026
Nexsen has secured ISO 13485 certification covering the design, development and manufacture of its StrepSure Group B Streptococcus diagnostic. The milestone strengthens the product’s regulatory and manufacturing platform, but does not yet amount to FDA or TGA approval.
Ada Torres
Ada Torres
2 Nov 2026
Felix Gold made substantial progress on its proposed Alaska antimony mine and US refinery during the September quarter, including 80 drill holes and pilot-scale production of cast antimony metal. The progress came at a cost: cash fell to A$1.267 million, equal to an estimated 0.1 quarters of funding on the quarter’s reported outgoings.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.
Victor Sage
Victor Sage
30 Oct 2026
Bio-Gene Technology has moved closer to two commercialisation milestones, with Qcide product work progressing in Japan and a first Flavocide regulatory submission targeted for Q2 2027. The company ended September with A$2.103 million in cash, equivalent to an estimated 2.18 quarters of funding at the quarter’s operating cash rate.
Victor Sage
Victor Sage
30 Oct 2026
BlinkLab has reported 82% sensitivity and 83% specificity from an exploratory ADHD study in 208 children, while preparing a US regulatory program for a second product. Its autism diagnostic remains on track for pivotal study completion this quarter, with A$16.2 million in cash at 30 September.
Victor Sage
Victor Sage
29 Oct 2026
Cambium Bio has moved Elate Ocular into Phase 3 manufacturing and submitted an updated CAMOMILE-2 protocol to the FDA. The company is targeting First Patient In by year-end, but that timetable depends on a conditional A$7.1 million placement, unsigned CRO agreements and release of the first clinical batch.
Ada Torres
Ada Torres
28 Oct 2026

Browse the archive

Full archive